Baxter International's stock plummeted after its fourth-quarter earnings report. The medtech giant's shares dropped by 14%, as investors reacted to disappointing financial results and a weak profit forecast for the upcoming year. The company's adjusted earnings per share of $0.44 fell short of the $0.54 analysts had anticipated, despite a revenue beat.

Revenue for the quarter reached $2.97 billion, surpassing the $2.84 billion consensus estimate. However, concerns over profitability overshadowed the sales figures. Baxter's guidance for adjusted earnings per share in fiscal year 2026, set at $1.85 to $2.05, fell significantly below the analyst consensus of $2.25, further fueling investor concerns about future performance.

Andrew Hider, Baxter's CEO, cited the company's focus on continuous improvement. Segment performance showed varied results, with Medical Products & Therapies sales rising 6%. The company also announced board changes, effective February 13, 2026. This disappointing news comes as Baxter implements a new operating model to simplify its organization.

Investors are clearly worried about Baxter's ability to meet future earnings expectations. The market reaction indicates a lack of confidence in the company's outlook, despite revenue growth. The steep decline in share price reflects the severity of the earnings miss and the negative implications of the weak profit guidance for the company's growth trajectory.